EDL-155

07/01/2010 - "EDL-155 appears to eliminate retinoblastoma cells by disrupting mitochondria and inducing autophagy. "
07/01/2010 - "EDL-155 appeared to destroy the retinoblastoma cells in vitro with an EC(50) of 9.1 micriM. "
07/01/2010 - "To evaluate the efficacy of EDL-155 in vivo, Y79-Luc retinoblastoma cells were injected into the vitreous cavity of newborn rats, followed by periocular injections of EDL-155 (20 mg/kg/day) or an equivalent dosage of saline. "
07/01/2010 - "In the retinoblastoma animal model, four doses of EDL-155 were delivered over 4 days, which was sufficient to see a significant decrease (P = 0.01) in viable intraocular tumors. "
05/01/2009 - "Fast and sensitive liquid chromatography/electrospray mass spectrometry method to study ocular penetration of EDL-155, a novel antitumor agent for retinoblastoma in rats."

05/01/2009 - "The assay was rapid, sensitive and robust enough to support EDL-155 ocular penetration studies in a rodent model of intraocular cancer. "
07/01/2010 - "Seven of the 25 rats treated with EDL-155 had no detectable living tumor. "
05/01/2008 - "Intracranial tumor volume at 7 days post-implantation was approximately 30% smaller in animals treated with EDL-155 when compared to vehicle control animals (13.2+/-5.3 mm(3) vs. 18.7+/-6.3 mm(3); P=0.04). "
07/01/2010 - "Local delivery of EDL-155 may be an effective therapy for some types of ocular cancers."
05/01/2009 - "High local concentrations coupled with minimal systemic exposure supports further testing of EDL-155 as localized therapy for intraocular cancers."

05/01/2008 - "In this study, peripheral and cerebrospinal fluid (CSF) pharmacokinetics in rats were determined to assess the drug developability of the novel THI EDL-155 for the treatment of glioma. "
10/01/2008 - "We observed anatomical changes in cultured glioma cells treated with EDL-155 that were consistent with selective destruction of mitochondria and the induction of autophagy. "
10/01/2008 - "The effect of EDL-155 was also tested in an animal model in which C6 glioma was transplanted into the brains of Sprague-Dawley rats. "
10/01/2008 - "Normal cultured rat astrocytes and C6 rat glioma were used as a differential screen to test the effects of EDL-155. "
10/01/2008 - "The selective killing of glioma in tissue culture and in the rat brain models indicates that EDL-155 has potential therapeutic value in treating this type of brain cancer."

05/01/2008 - "EDL-155 treatment resulted in reduced tumor size despite limited blood brain barrier penetrability, which suggests that analogs with increased metabolic stability and brain penetrability may provide a therapeutic option for primary central nervous system tumors such as glioma. "

05/01/2009 - "Our group has used the tetrahydroisoquinoline derivative EDL-155 to treat glioblastoma in animal models and it is currently being evaluated in the treatment of ocular cancers. "